

Singulex, Qiagen to develop companion diagnostics, 4/17

April 2017—Singulex has entered into a strategic collaboration with Qiagen to develop companion diagnostics. Through the collaboration, Qiagen will have access to Singulex's Single Molecule Counting (SMC) immunodiagnostic platform, adding immunoassay capabilities to Qiagen's existing molecular testing services for the development of companion diagnostics. Singulex believes the collaboration will expand the access and use of its proprietary SMC platform and is an important validation of high-sensitivity immunoassays and its versatility of applications. SMC is available via Singulex's CLIA-licensed laboratory, with future application through the SGX Clarity system, a fully automated IVD platform that is in development and not yet approved for sale.

[Singulex](#), 510-995-9000